Drug Type TIL therapy |
Synonyms CD40L TIL(H. Lee Moffitt Cancer Center and Research Institute) |
Target |
Action stimulants |
Mechanism CD40L stimulants(CD40 ligand stimulants), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | United States | 10 Mar 2023 | |
metastatic non-small cell lung cancer | Phase 2 | United States | 10 Mar 2023 | |
Recurrent Non-Small Cell Lung Cancer | Phase 2 | United States | 10 Mar 2023 | |
Non-Muscle Invasive Bladder Neoplasms | Phase 1 | United States | 10 Aug 2023 | |
Urothelial Carcinoma of the Urinary Bladder | Phase 1 | United States | 10 Aug 2023 |
Not Applicable | Non-Small Cell Lung Cancer PD-1+ | IFN-γ | 103 | (Initial Expansion (IE) TILs) | mfrcewmokp(pzsdlbbcfg) = egtnejzqpn kklaettkju (uielqfopxc, 0.02 - 30.8) View more | Positive | 07 Nov 2022 | |
(Rapid Expansion (REP) TILs) | hywxurbcfe(fnycmbogdd) = dlomifqkcj bpmondlshg (bsnkkksydz ) View more | ||||||
Phase 1 | 20 | Tumor-infiltrating Lymphocytes (TIL)+Nivolumab+Fludarabine+CYCLOPHOSPHAMIDE+Tumor-infiltrating Lymphocyte Therapy | xnedvhrvwq(rqopasmqjf) = vzxqumriei rbrhsjqlvm (vhcepkvmmv, wjqgnzeyhq - rhybjrsgwz) View more | - | 13 Apr 2022 | ||
Phase 2 | 56 | (ktywodmrys) = yufikkjwgj psfhbtsasu (dpdlwgzvrp ) | Positive | 20 May 2014 |